

# Laurence H Klotz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7660489/publications.pdf>

Version: 2024-02-01

418  
papers

23,253  
citations

14655

66  
h-index

9103

144  
g-index

460  
all docs

460  
docs citations

460  
times ranked

16803  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overdiagnosis in urologic cancer. World Journal of Urology, 2022, 40, 1-8.	2.2	14
2	The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 253-262.	3.0	21
3	Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29â€MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. Contemporary Clinical Trials, 2022, 112, 106618.	1.8	24
4	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
5	Low Serum Testosterone in Men with Newly Diagnosed Androgen-Deprivation Therapy-Naïve Prostate Cancer and Its Relationship to Cardiovascular Risk Factors: A RADICAL-PC Substudy. Journal of Urology, 2022, , 101097JU00000000000002384.	0.4	2
6	Effect of <sup>18</sup> F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology, 2022, 303, 414-422.	7.3	16
7	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.4	13
8	A protocol for the VISION study: An individual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultrasound guided biopsy in the detection of prostate cancer. PLoS ONE, 2022, 17, e0263345.	2.5	2
9	Focal therapy: definition and rationale. Current Opinion in Urology, 2022, 32, 218-223.	1.8	0
10	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
11	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	2.3	2
12	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
13	Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. European Urology Open Science, 2022, 41, 126-133.	0.4	5
14	Impact of COVID-19 on medical education: introducing homo digitalis. World Journal of Urology, 2021, 39, 1997-2003.	2.2	22
15	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	2.5	15
16	Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion) Tj ETQq0 0.0,rgBT /Overlock 10	2.2	6
17	Current evidence for focal therapy and partial gland ablation for organ-confined prostate cancer: systematic review of literature published in the last 2 years. Current Opinion in Urology, 2021, 31, 49-57.	1.8	7
18	Age-Related Mental Health Consequences of COVID-19: A Global Perspective. SociÃ©tÃ© Internationale D'urologie Journal, 2021, 2, 25-31.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. <i>European Urology Focus</i> , 2021, , .	3.1	3
20	The â€˜Câ€™ Words: parallels and analogies between Prostate Cancer and Covid-19. <i>World Journal of Urology</i> , 2021, 39, 3175-3176.	2.2	1
21	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 769-779.	0.4	45
22	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 779-779.	0.4	1
23	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 781.e17-781.e24.	1.6	10
24	The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 79, 446-452.	1.9	24
25	Incidental Prostate Cancer (cT1aâ€“cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. <i>European Urology Oncology</i> , 2021, , .	5.4	6
26	Comparison of Multiparametric Magnetic Resonance Imagingâ€“Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naïve Men at Risk for Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 534.	7.1	99
27	Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 1166-1176.	0.4	5
28	Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? <i>Eur Urol Oncol</i> . In press. <i>European Urology Oncology</i> , 2021, 5, 261-261.	5.4	0
29	Not So â€œActiveâ€•Surveillance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 716-717.	0.8	0
30	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1176.	0.4	0
31	Active surveillance in favorable intermediate-risk prostate cancer patients: Predictors of deferred intervention and treatment choice. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	5
32	Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients. <i>Urology</i> , 2021, 155, 117-123.	1.0	7
33	Re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of â€œManelsâ€•in Major Urology Meetings. <i>Eur Urol</i> 2021;80:442â€“9. <i>European Urology</i> , 2021, 80, e100.	1.9	6
34	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	5.4	24
35	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. <i>European Urology</i> , 2020, 77, 311-317.	1.9	99
36	Active surveillance in intermediateâ€“risk prostate cancer. <i>BJU International</i> , 2020, 125, 346-354.	2.5	59

#	ARTICLE	IF	CITATIONS
37	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020, 126, 583-592.	4.1	9
38	Can high resolution micro-ultrasound replace MRI in the diagnosis of prostate cancer?. <i>European Urology Focus</i> , 2020, 6, 419-423.	3.1	33
39	When to biopsy Prostate Imaging and Data Reporting System version 2 (PI-RADSv2) assessment category 3 lesions? Use of clinical and imaging variables to predict cancer diagnosis at targeted biopsy. <i>Canadian Urological Association Journal</i> , 2020, 15, 115-121.	0.6	7
40	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e1-929.e10.	1.6	7
41	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. <i>Canadian Urological Association Journal</i> , 2020, 15, 181-186.	0.6	13
42	Outreach and Influence of Surgical Societies'™ Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic'™An Anonymized International Urologic Expert Inquiry. <i>Urology</i> , 2020, 145, 73-78.	1.0	2
43	Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis. <i>Canadian Urological Association Journal</i> , 2020, 15, E11-E16.	0.6	48
44	Patients'™ perspective of telephone visits during the COVID-19 pandemic. <i>Canadian Urological Association Journal</i> , 2020, 14, E402-E406.	0.6	8
45	Cross'™continental comparison of safety and protection measures amongst urologists during COVID'™19. <i>International Journal of Urology</i> , 2020, 27, 981-989.	1.0	3
46	Scoping review: hotspots for COVID-19 urological research: what is being published and from where?. <i>World Journal of Urology</i> , 2020, 39, 3151-3160.	2.2	3
47	Systematic review and meta-analysis of trials evaluating the role of adjuvant radiation after radical prostatectomy for prostate cancer: Implications for early salvage. <i>Canadian Urological Association Journal</i> , 2020, 14, 330-336.	0.6	6
48	Impact of COVID-19 on Urology Practice: A Global Perspective and Snapshot Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1730.	2.4	16
49	Prioritising Urological Surgery in the COVID-19 Era: A Global Reflection on Guidelines. <i>European Urology Focus</i> , 2020, 6, 1104-1110.	3.1	20
50	Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 469-481.	3.8	29
51	The history of intermittent androgen- deprivation therapy '™ A Canadian story. <i>Canadian Urological Association Journal</i> , 2020, 14, 159-162.	0.6	7
52	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. <i>Canadian Urological Association Journal</i> , 2020, 14, E453-E457.	0.6	11
53	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 343-350.	1.9	33
54	Intermediate-risk Prostate Cancer: Stratification and Management. <i>European Urology Oncology</i> , 2020, 3, 270-280.	5.4	51

#	ARTICLE	IF	CITATIONS
55	Letter “Can micro-ultrasound be the new first-choice test for patients with a suspicion of prostate cancer?. Canadian Urological Association Journal, 2020, 15, E127-8.	0.6	1
56	Adding prostate-specific membrane antigen positron emission tomography (PSMA PET) to our prostate cancer armamentarium raises many questions. Canadian Urological Association Journal, 2020, 15, 179-80.	0.6	6
57	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1085-1093.	0.4	44
58	Extragenadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. Journal of Urology, 2020, 203, 940-948.	0.4	8
59	Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. Journal of Urology, 2020, 204, 416-426.	0.4	8
60	Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. Journal of Urology, 2020, 204, 466-475.	0.4	24
61	Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. Journal of Urology, 2020, 204, 934-940.	0.4	14
62	Analysis of small non-coding RNAs in urinary exosomes to classify prostate cancer into low-grade (GG1) and higher-grade (GG2-5).. Journal of Clinical Oncology, 2020, 38, 277-277.	1.6	1
63	The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.. Journal of Clinical Oncology, 2020, 38, 364-364.	1.6	6
64	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. Journal of Clinical Oncology, 2020, 38, 131-131.	1.6	2
65	Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.. Journal of Clinical Oncology, 2020, 38, 221-221.	1.6	0
66	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.4	0
67	Active surveillance for low-risk prostate cancer “in pursuit of a standardized protocol. Central European Journal of Urology, 2020, 73, 123-126.	0.3	1
68	Comparison of micro-ultrasound and multiparametric MRI imaging for prostate cancer: A multicenter prospective analysis.. Journal of Clinical Oncology, 2020, 38, 296-296.	1.6	0
69	Contribution of extragenadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy.. Journal of Clinical Oncology, 2020, 38, 148-148.	1.6	0
70	Reply by Authors. Journal of Urology, 2020, 204, 475-475.	0.4	0
71	Surveillance after prostate focal therapy. World Journal of Urology, 2019, 37, 397-407.	2.2	63
72	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases, 2019, 22, 24-38.	3.9	215

#	ARTICLE	IF	CITATIONS
73	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. <i>European Urology</i> , 2019, 75, 300-309.	1.9	99
74	Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large Canadian multi-institutional database. <i>Canadian Urological Association Journal</i> , 2019, 14, 24-30.	0.6	2
75	Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 84-86.	27.0	1
76	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	1.9	18
77	Value of Increasing Biopsy Cores per Target with Cognitive MRI-targeted Transrectal US Prostate Biopsy. <i>Radiology</i> , 2019, 291, 83-89.	7.3	43
78	Contemporary approach to active surveillance for favorable risk prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 146-152.	1.2	32
79	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 61-66.	0.8	8
80	Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 297.e9-297.e17.	1.6	21
81	Re: Prostate Cancer-specific Mortality Across Gleason Scores in Black vs Nonblack Men. <i>European Urology</i> , 2019, 75, 1036-1037.	1.9	1
82	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019, 2, 333-336.	5.4	8
83	Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model. <i>Anticancer Research</i> , 2019, 39, 113-118.	1.1	8
84	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019, 75, 523-531.	1.9	58
85	Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid receptor 2 dependent manner. <i>Prostate</i> , 2019, 79, 151-159.	2.3	49
86	Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 113-119.	0.4	57
87	Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. <i>Journal of Urology</i> , 2019, 201, 721-727.	0.4	15
88	Discordance between testosterone measurement methods in castrated prostate cancer patients. <i>Endocrine Connections</i> , 2019, 8, 132-140.	1.9	6
89	Impact of compliance on outcomes for patients on active surveillance for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 36-36.	1.6	1
90	A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 60-60.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Active surveillance in intermediate risk prostate cancer. Archivos Espanoles De Urologia, 2019, 72, 157-166.	0.2	1
92	Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance. Journal of Urology, 2018, 199, 1475-1481.	0.4	26
93	Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance. Prostate Cancer and Prostatic Diseases, 2018, 21, 187-195.	3.9	7
94	A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA "grey zone". World Journal of Urology, 2018, 36, 341-348.	2.2	11
95	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. Journal of Urology, 2018, 199, 990-997.	0.4	279
96	Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. Journal of Urology, 2018, 199, 683-690.	0.4	606
97	Prostate cancer prevention: proof is elusive. BJU International, 2018, 121, 487-488.	2.5	2
98	A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. Journal of Urology, 2018, 200, 335-343.	0.4	9
99	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine, 2018, 378, 1767-1777.	27.0	2,036
100	Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. Journal of Urology, 2018, 199, 147-154.	0.4	33
101	The future of active surveillance. Translational Andrology and Urology, 2018, 7, 256-259.	1.4	8
102	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	1.4	14
103	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urology, 2018, 18, 77.	1.4	2
104	Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer. JAMA Oncology, 2018, 4, 1133.	7.1	0
105	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. Clinical Cancer Research, 2018, 24, 5305-5312.	7.0	13
106	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Annals of Internal Medicine, 2018, 168, 1.	3.9	33
107	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. European Urology Oncology, 2018, 1, 238-241.	5.4	25
108	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. European Urology, 2017, 71, 648-655.	1.9	190



#	ARTICLE	IF	CITATIONS
109	The drama of prostate cancer diagnostics. <i>Lancet Oncology</i> , The, 2017, 18, e132.	10.7	2
110	Active surveillance for low-risk prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 225-230.	1.8	37
111	Semantics in active surveillance for men with localized prostate cancer – results of a modified Delphi consensus procedure. <i>Nature Reviews Urology</i> , 2017, 14, 312-322.	3.8	65
112	Contemporary Active Surveillance. <i>Urologic Clinics of North America</i> , 2017, 44, 565-574.	1.8	20
113	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. <i>BMJ Open</i> , 2017, 7, e017863.	1.9	14
114	Active Surveillance for Intermediate Risk Prostate Cancer. <i>Current Urology Reports</i> , 2017, 18, 80.	2.2	29
115	The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 1068-1075.	0.4	33
116	Appropriateness Criteria for Active Surveillance of Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 67-74.	0.4	43
117	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. <i>European Urology</i> , 2017, 71, 534-542.	1.9	28
118	Evaluation of Focal Ablation of Magnetic Resonance Imaging Defined Prostate Cancer Using Magnetic Resonance Imaging Controlled Transurethral Ultrasound Therapy with Prostatectomy as the Reference Standard. <i>Journal of Urology</i> , 2017, 197, 255-261.	0.4	28
119	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , 2017, 197, 335-341.	0.4	39
120	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	1.9	11
121	Testosterone suppression in the treatment of recurrent or metastatic prostate cancer – A Canadian consensus statement. <i>Canadian Urological Association Journal</i> , 2017, 12, 30-7.	0.6	16
122	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 16.	0.6	20
123	Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 62.	0.6	0
124	Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. <i>Canadian Urological Association Journal</i> , 2017, 12, E59-63.	0.6	1
125	What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?. <i>Canadian Urological Association Journal</i> , 2017, 11, 118.	0.6	2
126	Active Surveillance for Low Risk Prostate Cancer. , 2017, , 161-170.		1



#	ARTICLE	IF	CITATIONS
127	Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells. <i>Anticancer Research</i> , 2017, 37, 6601-6607.	1.1	5
128	Low-Risk Prostate Cancer in North America: Rationale, Uptake, and Limitations of Active Surveillance and Opportunities for Focal Therapy. <i>Current Clinical Urology</i> , 2017, , 51-56.	0.0	0
129	Active Surveillance for Prostate Cancer: How to Do It Right. <i>Oncology</i> , 2017, 31, 333-40, 345.	0.5	23
130	The uptake of active surveillance for the management of prostate cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 333.	0.6	17
131	Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer. <i>Journal of Urology</i> , 2016, 196, 309-311.	0.4	2
132	Overtreatment in cancer “is it a problem?”. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1-5.	1.8	22
133	Intermittent Androgen Deprivation Therapy“An Important Treatment Option for Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1531.	7.1	11
134	Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience. <i>Journal of Urology</i> , 2016, 196, 1651-1658.	0.4	157
135	Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression. <i>Journal of Urology</i> , 2016, 196, 986-988.	0.4	6
136	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 153-163.	10.7	210
137	Active Surveillance: Rationale, Patient Selection, Follow-up, and Outcomes. , 2016, , 215-223.		0
138	Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials. <i>Therapeutic Advances in Urology</i> , 2016, 8, 75-82.	2.0	15
139	Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance. <i>Journal of Urology</i> , 2016, 195, 1409-1414.	0.4	98
140	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>European Urology</i> , 2016, 69, 933-941.	1.9	16
141	Current Status of Clinical Trials in Active Surveillance. , 2016, , 141-152.		0
142	Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5063-5063.	1.6	0
143	A prospective comparison of MRI“US fused targeted biopsy versus systematic ultrasound“guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 220-225.	3.4	82
144	Capsaicin reduces the metastatic burden in the transgenic adenocarcinoma of the mouse prostate model. <i>Prostate</i> , 2015, 75, 1300-1311.	2.3	54

#	ARTICLE	IF	CITATIONS
145	Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU International, 2015, 116, 213-219.	2.5	20
146	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. Journal of Cancer, 2015, 6, 1160-1171.	2.5	32
147	Active surveillance for the management of localized prostate cancer: Guideline recommendations. Canadian Urological Association Journal, 2015, 9, 171.	0.6	184
148	The Effects of Serum from Prostate Cancer Patients with Elevated Body Mass Index on Prostate Cancer Cells in Vitro. Lipid Insights, 2015, 8, LPI.S23135.	1.0	14
149	Complications After Radical Prostatectomy or Radiotherapy for Prostate Cancer: Results of a Population-based, Propensity Score-matched Analysis. Urology, 2015, 85, 621-628.	1.0	34
150	Survivorship and Improving Quality of Life in Men with Prostate Cancer. European Urology, 2015, 68, 374-383.	1.9	91
151	Defining "progression" and triggers for curative intervention during active surveillance. Current Opinion in Urology, 2015, 25, 258-266.	1.8	14
152	Testosterone therapy and prostate cancer safety concerns are well founded. Nature Reviews Urology, 2015, 12, 48-54.	3.8	21
153	Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. European Urology, 2015, 67, 627-636.	1.9	284
154	Active Surveillance for Low-risk Prostate Cancer: Developments to Date. European Urology, 2015, 67, 646-648.	1.9	25
155	Cleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. Journal of Urology, 2015, 194, 79-84.	0.4	68
156	Active Surveillance for Prostate Cancer: Debate over the Application, Not the Concept. European Urology, 2015, 67, 1006-1008.	1.9	7
157	A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. Biochemical and Biophysical Research Communications, 2015, 464, 848-854.	2.1	22
158	Active Surveillance for Low-Risk Prostate Cancer. Current Urology Reports, 2015, 16, 24.	2.2	36
159	Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT. Journal of Clinical Oncology, 2015, 33, 1151-1156.	1.6	139
160	Management of low- and intermediate-risk prostate cancer. World Journal of Urology, 2015, 33, 905-906.	2.2	2
161	Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World Journal of Urology, 2015, 33, 907-916.	2.2	19
162	Editorial Comment. Urology, 2015, 86, 996.	1.0	0

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1795-1802.	3.3	15
164	Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 272-277.	1.6	985
165	World Urologic Oncology Federation Bladder Cancer Prevention Program: A global initiative. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 25-29.	1.6	26
166	Capsaicin: A novel radio-sensitizing agent for prostate cancer. Prostate, 2015, 75, 113-125.	2.3	41
167	Active surveillance and focal therapy for low-intermediate risk prostate cancer. Translational Andrology and Urology, 2015, 4, 342-54.	1.4	22
168	Practice patterns of post-radical prostatectomy incontinence surgery in Ontario. Canadian Urological Association Journal, 2014, 8, 670.	0.6	4
169	Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial. Canadian Urological Association Journal, 2014, 8, 789.	0.6	9
170	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	2.8	41
171	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the British Society of Urological Pathology. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1395.	2.5	117
172	GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Contributed equally and share first authorship.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1126-1134.	1.6	60
173	Active surveillance for clinically localized prostate cancer—A systematic review. Journal of Surgical Oncology, 2014, 109, 830-835.	1.7	139
174	Management of low risk prostate cancer. Current Opinion in Urology, 2014, 24, 270-279.	1.8	24
175	Conservative management for low-risk prostate cancer improves quality-adjusted life expectancy at lower cost compared with initial treatment. Evidence-Based Medicine, 2014, 19, 40-40.	0.6	0
176	Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. European Urology, 2014, 65, 565-573.	1.9	276
177	Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncology, The, 2014, 15, 223-231.	10.7	203
178	Reply by the Authors. Urology, 2014, 84, 1250-1251.	1.0	0
179	Clinical trial risk in castration-resistant prostate cancer: immunotherapies show promise. BJU International, 2014, 113, E82-E89.	2.5	9
180	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. European Urology, 2014, 66, 619-622.	1.9	57

#	ARTICLE	IF	CITATIONS
181	Maximal Testosterone Suppression in Prostate Cancer—Free vs Total Testosterone. <i>Urology</i> , 2014, 83, 1217-1222.	1.0	16
182	Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists. <i>European Urology</i> , 2014, 66, 1101-1108.	1.9	90
183	Long-term Tolerability and Efficacy of Degarelix: 5-Year Results From a Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix. <i>Urology</i> , 2014, 83, 1122-1128.	1.0	50
184	Management of low risk prostate cancer—active surveillance and focal therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 324-334.	27.6	61
185	Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. <i>Oncology</i> , 2014, 28, 950-C3.	0.5	7
186	Intermittent Androgen Deprivation Therapy: Clarity from Confusion. <i>European Urology</i> , 2013, 64, 731-733.	1.9	3
187	Intermittent Versus Continuous Androgen Deprivation Therapy in Advanced Prostate Cancer. <i>Current Urology Reports</i> , 2013, 14, 159-167.	2.2	15
188	Exercise Does Not Counteract the Effects of a “Westernized” Diet on Prostate Cancer Xenografts. <i>Prostate</i> , 2013, 73, 1223-1232.	2.3	8
189	Image-Guided Prostate Biopsy Using Magnetic Resonance Imaging—Derived Targets: A Systematic Review. <i>European Urology</i> , 2013, 63, 125-140.	1.9	479
190	Strengthening evidence for active surveillance for prostate cancer. <i>European Urology</i> , 2013, 63, 108-110.	1.9	4
191	A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study. <i>European Urology</i> , 2013, 63, 927-935.	1.9	64
192	Standards of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate: Recommendations from an International Working Group. <i>European Urology</i> , 2013, 64, 544-552.	1.9	383
193	Active Surveillance, Quality of Life, and Cancer-related Anxiety. <i>European Urology</i> , 2013, 64, 37-39.	1.9	26
194	Active surveillance for low-risk prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 295-302.	4.4	46
195	Active Surveillance for Prostate Cancer: Overview and Update. <i>Current Treatment Options in Oncology</i> , 2013, 14, 97-108.	3.0	57
196	Active surveillance. <i>Current Opinion in Urology</i> , 2013, 23, 237-238.	1.8	3
197	Prostate cancer overdiagnosis and overtreatment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 204-209.	2.3	105
198	Active surveillance. <i>Current Opinion in Urology</i> , 2013, 23, 239-244.	1.8	42

#	ARTICLE	IF	CITATIONS
199	Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Canadian Urological Association Journal, 2013, 7, 450.	0.6	5
200	Still unconvinced on the use of salvage prostatectomy. Canadian Urological Association Journal, 2013, 7, 93.	0.6	1
201	MR thermometry in the human prostate gland at 3.0T for transurethral ultrasound therapy. Journal of Magnetic Resonance Imaging, 2013, 38, 1564-1571.	3.4	26
202	Randomized Clinical Trial of Vitamin D3 Doses on Prostatic Vitamin D Metabolite Levels and Ki67 Labeling in Prostate Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1498-1507.	3.6	81
203	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. Journal of the National Cancer Institute, 2013, 105, 1050-1058.	6.3	208
204	Meeting your high expectations. Canadian Urological Association Journal, 2013, 2, 595.	0.6	0
205	Health advocacy in urology training. Canadian Urological Association Journal, 2013, 1, 356.	0.6	0
206	Un plaidoyer pour la santé dans la formation en urologie. Canadian Urological Association Journal, 2013, 1, 357.	0.6	0
207	Does screening for prostate cancer reduce prostate cancer mortality?. Canadian Urological Association Journal, 2013, 3, 187.	0.6	2
208	CUA: making Canada proud at the AUA. Canadian Urological Association Journal, 2013, 3, 185.	0.6	0
209	The importance of feedback. Canadian Urological Association Journal, 2013, 3, 9.	0.6	1
210	Indexation !!!.. Canadian Urological Association Journal, 2013, 2, 91.	0.6	0
211	Indexation: not quite yet. Canadian Urological Association Journal, 2013, 2, 169.	0.6	0
212	The improved CUA Office of Education. Canadian Urological Association Journal, 2013, 2, 491.	0.6	0
213	Improving quality of care. Canadian Urological Association Journal, 2013, 4, 299.	0.6	4
214	An unsung Canadian hero!. Canadian Urological Association Journal, 2013, 4, 371.	0.6	0
215	The editor is back. Canadian Urological Association Journal, 2013, 3, 277.	0.6	0
216	EBM in Canadian urology. Canadian Urological Association Journal, 2013, 4, 83.	0.6	0

#	ARTICLE	IF	CITATIONS
217	The impact of surgical complexities. Canadian Urological Association Journal, 2013, 2, 9.	0.6	0
218	The bright future of the CUA. Canadian Urological Association Journal, 2013, 2, 365.	0.6	0
219	The case for prostate capsule-sparing radical cystectomy in selected patients. Canadian Urological Association Journal, 2013, 3, 215.	0.6	4
220	Prostate cancer screening: Canadian guidelines 2011. Canadian Urological Association Journal, 2013, 5, 235.	0.6	0
221	Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists. Canadian Urological Association Journal, 2013, 3, 460.	0.6	3
222	Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.. Journal of Clinical Oncology, 2013, 31, 1-1.	1.6	2
223	Comparison of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists.. Journal of Clinical Oncology, 2013, 31, 42-42.	1.6	4
224	Active Surveillance for Favorable-Risk Prostate Cancer. , 2013, , 621-629.		4
225	Gleason grading controversies: what the chemoprevention trials have taught us. Canadian Urological Association Journal, 2013, 3, 115.	0.6	2
226	Active surveillance not only reduces morbidity, It saves lives. Oncology, 2013, 27, 522, 593.	0.5	1
227	Active Surveillance: The Canadian Experience With an "Inclusive Approach". Journal of the National Cancer Institute Monographs, 2012, 2012, 234-241.	2.1	21
228	Active surveillance. Current Opinion in Urology, 2012, 22, 222-230.	1.8	25
229	Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. New England Journal of Medicine, 2012, 367, 895-903.	27.0	428
230	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. Canadian Urological Association Journal, 2012, 6, 83-88.	0.6	7
231	Publishing in Urology: My 20-year journey. Canadian Urological Association Journal, 2012, 6, 223-223.	0.6	0
232	Cancer overdiagnosis and overtreatment. Current Opinion in Urology, 2012, 22, 203-209.	1.8	61
233	How (not) to communicate new scientific information: a memoir of the famous Brindley lecture. Trends in Urology & Men's Health, 2012, 3, 35-36.	0.4	0
234	Active Surveillance for Prostate Cancer: A Systematic Review of the Literature. European Urology, 2012, 62, 976-983.	1.9	518

#	ARTICLE	IF	CITATIONS
235	Impact of Multiparametric Endorectal Coil Prostate Magnetic Resonance Imaging on Disease Reclassification Among Active Surveillance Candidates: A Prospective Cohort Study. Journal of Urology, 2012, 187, 1247-1252.	0.4	157
236	Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists. Canadian Urological Association Journal, 2012, 1, S69-70.	0.6	1
237	The uses of error. Canadian Urological Association Journal, 2012, 1, 235.	0.6	0
238	Active Surveillance for Favorable-risk Prostate Cancer: Background, Patient Selection, Triggers for Intervention, and Outcomes. Current Urology Reports, 2012, 13, 153-159.	2.2	29
239	Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU International, 2012, 109, 1-7.	2.5	17
240	Gonadotropin-releasing hormone: An update review of the antagonists versus agonists. International Journal of Urology, 2012, 19, 594-601.	1.0	88
241	Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature. European Urology, 2012, 61, 961-971.	1.9	238
242	Comment on the US Preventive Services Task Force's Draft Recommendation on Screening for Prostate Cancer. European Urology, 2012, 61, 851-854.	1.9	11
243	Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort. BJU International, 2012, 110, 195-200.	2.5	19
244	Active Surveillance: The Canadian Experience. , 2012, , 95-105.		2
245	Active surveillance for low-risk prostate cancer. F1000 Medicine Reports, 2012, 4, 16.	2.9	10
246	Active Surveillance Comes of Age. , 2012, , 215-223.		0
247	Active Surveillance for Favorable Risk Prostate Cancer: Background, Patient Selection, Triggers for Intervention, and Outcomes. , 2012, , 85-91.		0
248	Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.. Journal of Clinical Oncology, 2012, 30, 30-30.	1.6	1
249	Role of 5-alpha-reductase inhibitors in active surveillance of patients with low-risk prostate cancer.. Journal of Clinical Oncology, 2012, 30, 14-14.	1.6	0
250	Tout est dans l'emplacement : des biopsies prostatiques et de l'IRM. Canadian Urological Association Journal, 2012, 6, 81-81.	0.6	0
251	High-dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. FASEB Journal, 2012, 26, 388.5.	0.5	0
252	1293 PREVIOUSLY DEVELOPED SYSTEMS-BASED BIOPSY MODEL (PROSTATE PX+) IDENTIFIES FAVORABLE-RISK PROSTATE CANCER FOR MEN ENROLLED IN AN ACTIVE SURVEILLANCE PROGRAM. Journal of Urology, 2011, 185, .	0.4	5



#	ARTICLE	IF	CITATIONS
253	Statin Clinical Trial (REALITY) for Prostate Cancer: an Over 15-Year Wait is Finally Over Thanks to a Dietary Supplement. Urologic Clinics of North America, 2011, 38, 325-331.	1.8	14
254	Feasibility and Safety of Silicone Rubber Contrast-Enhanced Microcomputed Tomography in Evaluating the Angioarchitecture of Prostatectomy Specimens. Translational Oncology, 2011, 4, 173-177.	3.7	2
255	Gonadotropin-Releasing Hormone Blockers and Cardiovascular Disease Risk: Analysis of Prospective Clinical Trials of Degarelix. Journal of Urology, 2011, 186, 1835-1842.	0.4	53
256	Age-related properties of the tumour vasculature in renal cell carcinoma. BJU International, 2011, 107, 416-424.	2.5	23
257	Prostate cancer immunology – an update for Urologists. BJU International, 2011, 107, 1046-1051.	2.5	19
258	A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology, 2011, 59, 543-552.	1.9	910
259	Growth Kinetics of Renal Masses: Analysis of a Prospective Cohort of Patients Undergoing Active Surveillance. European Urology, 2011, 59, 863-867.	1.9	143
260	Early Prostate Cancer – Treat or Watch?. New England Journal of Medicine, 2011, 365, 568-569.	27.0	22
261	Active surveillance for low-risk prostate cancer: an update. Nature Reviews Urology, 2011, 8, 312-320.	3.8	63
262	Vitamin E and the Risk of Prostate Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1549.	7.4	1,458
263	Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators. Journal of Clinical Oncology, 2011, 29, 2959-2964.	1.6	86
264	The decline and fall of RCTs. Canadian Urological Association Journal, 2011, 5, 229-229.	0.6	1
265	Prostate cancer screening: Canadian guidelines 2011. Canadian Urological Association Journal, 2011, 5, 235-240.	0.6	50
266	Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. Journal of Clinical Oncology, 2011, 29, 3443-3449.	1.6	222
267	New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biology and Therapy, 2011, 12, 997-1004.	3.4	32
268	Active Surveillance for Prostate Cancer: Progress and Promise. Journal of Clinical Oncology, 2011, 29, 3669-3676.	1.6	264
269	CUAJ implements early releases. Canadian Urological Association Journal, 2011, 5, 7-7.	0.6	1
270	USPSTF and FDA: PSA and 5ARIs. Canadian Urological Association Journal, 2011, 5, 373-374.	0.6	1

#	ARTICLE	IF	CITATIONS
271	JALUC met en oeuvre les âœsorties prÂ©maturÂ©esâœ Canadian Urological Association Journal, 2011, 5, 9-9.	0.6	0
272	Le dÂ©clin et la chute des ECR. Canadian Urological Association Journal, 2011, 5, 231-231.	0.6	0
273	Lâ€™USPSTF et la FDA: Lâ€™APS et les I5AR. Canadian Urological Association Journal, 2011, 5, 375-376.	0.6	0
274	Active surveillance for prostate cancer: a review. Archivos Espanoles De Urologia, 2011, 64, 806-14.	0.2	10
275	Dietary Agents for Prostate Cancer Chemoprevention: An Overview. Current Cancer Therapy Reviews, 2010, 6, 308-316.	0.3	3
276	Active Surveillance for Prostate Cancer: A Review. Current Urology Reports, 2010, 11, 165-171.	2.2	77
277	Re: Effect of Dutasteride on the Risk of Prostate Cancer. European Urology, 2010, 58, 313.	1.9	2
278	Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review. Korean Journal of Urology, 2010, 51, 665.	1.2	12
279	Reply to F. Campodonico et al. Journal of Clinical Oncology, 2010, 28, e212-e212.	1.6	0
280	Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 126-131.	1.6	1,011
281	Reply to P.B. Singh et al. Journal of Clinical Oncology, 2010, 28, e514-e514.	1.6	1
282	Active Surveillance for Prostate Cancer. JAMA - Journal of the American Medical Association, 2010, 304, 2411.	7.4	37
283	Reply to J.B. Aragon-Ching. Journal of Clinical Oncology, 2010, 28, e267-e267.	1.6	0
284	Comparing Prostate Specific Antigen Triggers for Intervention in Men With Stable Prostate Cancer on Active Surveillance. Journal of Urology, 2010, 184, 1942-1946.	0.4	60
285	Prostate Cancer Death of Men Treated With Initial Active Surveillance: Clinical and Biochemical Characteristics. Journal of Urology, 2010, 184, 131-135.	0.4	82
286	Increasing Hospital Admission Rates for Urological Complications After Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology, 2010, 183, 963-969.	0.4	378
287	Antiproliferative Mechanisms of the Flavonoids 2,2â€²-Dihydroxychalcone and Fisetin in Human Prostate Cancer Cells. Nutrition and Cancer, 2010, 62, 668-681.	2.0	33
288	Protective effect of metformin in CD1 mice placed on a high carbohydrateâœ“high fat diet. Biochemical and Biophysical Research Communications, 2010, 397, 537-542.	2.1	40

#	ARTICLE	IF	CITATIONS
289	MRI-guided Transurethral Ultrasound Therapy of the Prostate Gland Using Real-time Thermal Mapping: Initial Studies. <i>Urology</i> , 2010, 76, 1506-1511.	1.0	71
290	Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer. <i>Journal of Urology</i> , 2010, 184, 2313-2319.	0.4	67
291	What Can Surrogate Tissues Tell Us about the Oxidative Stress Status of the Prostate? A Hypothesis-Generating In-Vivo Study. <i>PLoS ONE</i> , 2010, 5, e15880.	2.5	5
292	Using consensus guidelines effectively. <i>Canadian Urological Association Journal</i> , 2010, 4, 7-8.	0.6	0
293	A Combination of Micronutrients Is Beneficial in Reducing the Incidence of Prostate Cancer and Increasing Survival in the <i>Lady</i> Transgenic Model. <i>Cancer Prevention Research</i> , 2009, 2, 473-483.	1.5	41
294	Emerging drugs for prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 455-470.	2.4	7
295	Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1787-1793.	7.0	54
296	Review: Prostate capsule sparing radical cystectomy: oncologic safety and clinical outcome. <i>Therapeutic Advances in Urology</i> , 2009, 1, 43-50.	2.0	9
297	The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 81-86.	1.6	31
298	Analysis of the spatial and temporal accuracy of heating in the prostate gland using transurethral ultrasound therapy and active MR temperature feedback. <i>Physics in Medicine and Biology</i> , 2009, 54, 2615-2633.	3.0	65
299	Active Surveillance for Favorable Risk Prostate Cancer. <i>Journal of Urology</i> , 2009, 182, 2565-2566.	0.4	1
300	Degarelix acetate for the treatment of prostate cancer. <i>Drugs of Today</i> , 2009, 45, 725-30.	1.1	2
301	Active surveillance for prostate cancer: trials and tribulations. <i>World Journal of Urology</i> , 2008, 26, 437-442.	2.2	61
302	The impact of diet and micronutrient supplements on the expression of neuroendocrine markers in murine <i>Lady</i> transgenic prostate. <i>Prostate</i> , 2008, 68, 345-353.	2.3	11
303	The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. <i>BJU International</i> , 2008, 102, 1531-1538.	2.5	516
304	Quality of Life, Morbidity, and Mortality Results of a Prospective Phase II Study of Intermittent Androgen Suppression for Men with Evidence of Prostate-Specific Antigen Relapse After Radiation Therapy for Locally Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 46-52.	1.9	46
305	Re: Cumulative Association of Five Genetic Variants with Prostate Cancer. <i>European Urology</i> , 2008, 53, 1298-1299.	1.9	1
306	Active Surveillance for Favorable Risk Prostate Cancer: What Are the Results, and How Safe Is It?. <i>Seminars in Radiation Oncology</i> , 2008, 18, 2-6.	2.2	25

#	ARTICLE	IF	CITATIONS
307	Maximal androgen blockade for advanced prostate cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 331-340.	4.7	43
308	What is the best approach for screen-detected low volume cancers?â€”The case for observation. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 495-499.	1.6	11
309	A phase I trial of pre-operative radiotherapy for prostate cancer: Clinical and translational studies. Radiotherapy and Oncology, 2008, 88, 53-60.	0.6	30
310	Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention. Nature Reviews Urology, 2008, 5, 2-3.	1.4	25
311	Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nature Reviews Urology, 2008, 5, 362-363.	1.4	4
312	L'effet des complexit�s chirurgicales. Canadian Urological Association Journal, 2008, 2, 11.	0.6	0
313	Active surveillance for favorable-risk prostate cancer: who, how and why?. Nature Clinical Practice Oncology, 2007, 4, 692-698.	4.3	31
314	Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts. Journal of the National Cancer Institute, 2007, 99, 1793-1800.	6.3	160
315	Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biology and Therapy, 2007, 6, 40-45.	3.4	151
316	Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men. JAMA - Journal of the American Medical Association, 2007, 297, 1651.	7.4	1
317	Point: Active Surveillance for Favorable Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 693-698.	4.9	3
318	Urothelial Carcinoma of the Prostate. Urology, 2007, 69, 50-61.	1.0	62
319	Results of Unilateral Genitofemoral Nerve Grafts with Contralateral Nerve Sparing During Radical Prostatectomy. Urology, 2007, 69, 1161-1164.	1.0	12
320	Active surveillance for favorable risk prostate cancer: Rationale, risks, and results. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 505-509.	1.6	29
321	The Continuing Role of PSA in the Detection and Management of Prostate Cancer. European Urology Supplements, 2007, 6, 327-333.	0.1	7
322	Localised and Locally Advanced Prostate Cancer: Who to Treat and How?. European Urology Supplements, 2007, 6, 334-343.	0.1	4
323	Advanced Prostate Cancer: Hormones and Beyond. European Urology Supplements, 2007, 6, 354-364.	0.1	5
324	A new journal and new opportunities. Canadian Urological Association Journal, 2007, 1, 9.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Un nouveau journal et de nouvelles possibilités. Canadian Urological Association Journal, 2007, 1, 11.	0.6	0
326	Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer, 2007, 109, 858-867.	4.1	66
327	A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology, 2007, 51, 1606-1615.	1.9	572
328	Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?. Current Urology Reports, 2007, 8, 341-344.	2.2	4
329	PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. Canadian Urological Association Journal, 2007, 1, 17-21.	0.6	12
330	Combined Androgen Blockade: An Update. Urologic Clinics of North America, 2006, 33, 161-166.	1.8	16
331	Current Role of PSA Kinetics in the Management of Patients with Prostate Cancer. European Urology Supplements, 2006, 5, 472-478.	0.1	6
332	Active Surveillance with Selective Delayed Intervention for Favourable Risk Prostate Cancer: Clinical Experience and a 'Number Needed to Treat' Analysis. European Urology Supplements, 2006, 5, 479-486.	0.1	12
333	Modeling Prostate Specific Antigen Kinetics in Patients on Active Surveillance. Journal of Urology, 2006, 176, 1392-1398.	0.4	60
334	Cardiovascular effects of androgen depletion and replacement therapy. Urology, 2006, 67, 1126-1132.	1.0	8
335	Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 46-50.	1.6	107
336	Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. BJU International, 2006, 97, 451-455.	2.5	13
337	Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Current Treatment Options in Oncology, 2006, 7, 355-362.	3.0	66
338	Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer. Cancer, 2006, 107, 389-395.	4.1	98
339	Variants of the hK2 Protein Gene (KLK2) Are Associated with Serum hK2 Levels and Predict the Presence of Prostate Cancer at Biopsy. Clinical Cancer Research, 2006, 12, 6452-6458.	7.0	38
340	Out of country health care. Canadian Journal of Urology, 2006, 13, 2947.	0.0	0
341	Androgen replacement and/or 5 alpha reductase inhibitors in aging men. Canadian Journal of Urology, 2006, 13 Suppl 1, 44-5.	0.0	0
342	Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Canadian Journal of Urology, 2006, 13 Suppl 1, 48-55.	0.0	14

#	ARTICLE	IF	CITATIONS
343	PSA recurrence: definitions, PSA kinetics, and identifying patients at risk. Canadian Journal of Urology, 2006, 13 Suppl 2, 43-7.	0.0	5
344	How (not) to communicate new scientific information: a memoir of the famous brindley lecture. BJU International, 2005, 96, 956-957.	2.5	10
345	Active Surveillance with Selective Delayed Intervention Using PSA Doubling Time for Good Risk Prostate Cancer. European Urology, 2005, 47, 16-21.	1.9	73
346	Active Surveillance for Prostate Cancer: For Whom?. Journal of Clinical Oncology, 2005, 23, 8165-8169.	1.6	317
347	The Use of Genetic Markers to Determine Risk for Prostate Cancer at Prostate Biopsy. Clinical Cancer Research, 2005, 11, 8391-8397.	7.0	52
348	Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nature Reviews Urology, 2005, 2, 136-142.	1.4	40
349	Combined Androgen Blockade: The Case for Bicalutamide. Clinical Prostate Cancer, 2005, 3, 215-219.	2.1	29
350	Live donor nephrectomy. Canadian Journal of Urology, 2005, 12, 2506.	0.0	0
351	Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease. Canadian Journal of Urology, 2005, 12 Suppl 1, 53-7; discussion 101-2.	0.0	5
352	International regional working groups on prostate cancer: results of consensus development. Canadian Journal of Urology, 2005, 12 Suppl 1, 86-91.	0.0	1
353	Active surveillance for good risk prostate cancer: rationale, method, and results. Canadian Journal of Urology, 2005, 12 Suppl 2, 21-4.	0.0	9
354	Impact of the Chaouli decision. Canadian Journal of Urology, 2005, 12, 2726.	0.0	0
355	Seeing is believing: image guided therapy in urology. Canadian Journal of Urology, 2005, 12, 2870.	0.0	0
356	Antioxidants Block Prostate Cancer in Lady Transgenic Mice. Cancer Research, 2004, 64, 5891-5896.	0.9	112
357	Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU International, 2004, 94, 295-298.	2.5	29
358	Variation in patterns of practice in diagnosing screen-detected prostate cancer. BJU International, 2004, 94, 1239-1244.	2.5	13
359	ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER. Journal of Urology, 2004, 172, S48-50; discussion S50-1.	0.4	85
360	Endo urology and uro oncology. Canadian Journal of Urology, 2004, 11, 2108.	0.0	0

#	ARTICLE	IF	CITATIONS
361	A systematic review of randomized trials in localized prostate cancer. Canadian Journal of Urology, 2004, 11, 2110-7.	0.0	28
362	Practice patterns of Canadian urologists in the management of stage I testicular seminoma. Canadian Journal of Urology, 2004, 11, 2194-9.	0.0	6
363	Geopolitics and the CJU. Canadian Journal of Urology, 2004, 11, 2169-70.	0.0	0
364	'Gammon's law and a change in thinking?'. Canadian Journal of Urology, 2004, 11, 2226.	0.0	0
365	Restoring sexual function in prostate cancer patients: an innovative approach. Canadian Journal of Urology, 2004, 11, 2285-9.	0.0	14
366	Industry sponsored research. Canadian Journal of Urology, 2004, 11, 2312-3.	0.0	0
367	Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?. Seminars in Oncology, 2003, 30, 587-595.	2.2	5
368	Active Surveillance with Selective Delayed Intervention: A Biologically Nuanced Approach to Favorable-Risk Prostate Cancer. Clinical Prostate Cancer, 2003, 2, 106-110.	2.1	10
369	Selling ourselves short. Canadian Journal of Urology, 2003, 10, 1969.	0.0	3
370	Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors. Urology, 2002, 59, 551-554.	1.0	16
371	Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology, 2002, 60, 93-97.	1.0	115
372	Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology, 2002, 60, 201-208.	1.0	83
373	Reactions. Lancet, The, 2002, 360, 1869.	13.7	0
374	Expectant management with selective delayed intervention for favorable risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 175-179.	1.6	19
375	Feasibility Study: Watchful Waiting For Localized Low To Intermediate Grade Prostate Carcinoma With Selective Delayed Intervention Based On Prostate Specific Antigen, Histological And/Or Clinical Progression. Journal of Urology, 2002, 167, 1664-1669.	0.4	309
376	Modulation of Cell Proliferation and Cell Cycle Regulators by Vitamin E in Human Prostate Carcinoma Cell Lines. Journal of Urology, 2002, 168, 1578-1582.	0.4	82
377	Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clinical Biochemistry, 2002, 35, 471-475.	1.9	23
378	Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. UroOncology, 2002, 2, 93-94.	0.1	0



#	ARTICLE	IF	CITATIONS
379	Gender assignment and ideology. Canadian Journal of Urology, 2002, 9, 1442.	0.0	0
380	Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. Journal of Urology, 2002, 167, 1664-9.	0.4	80
381	Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Research, 2002, 62, 2540-5.	0.9	57
382	Guidelines and trials. Canadian Journal of Urology, 2002, 9, 1623.	0.0	0
383	Romanow, Romanow, wherefore art thou Romanow?. Canadian Journal of Urology, 2002, 9, 1672.	0.0	0
384	Back to nephrectomy for patients with metastatic renal cancer. Lancet, The, 2001, 358, 948-949.	13.7	6
385	Editorial 1240 1240 Laurence H. Klotz EDITORIAL. Canadian Journal of Urology, 2001, 8, 1240.	0.0	0
386	Intraoperative cavernous nerve stimulation during nerve sparing radical prostatectomy: how and when?. Current Opinion in Urology, 2000, 10, 239-243.	1.8	28
387	Early Postsurgery Experience of Prostate Cancer Patients and Spouses. Cancer Practice, 2000, 8, 165-171.	0.7	45
388	RE: EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER. Journal of Urology, 2000, 164, 1666-1666.	0.4	6
389	Presurgery Experiences of Prostate Cancer Patients and Their Spouses. Cancer Practice, 1999, 7, 130-135.	0.7	132
390	CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Urology, 1999, 53, 757-763.	1.0	69
391	Advances in nerve sparing for radical prostatectomy. Urology, 1999, 54, 956-959.	1.0	13
392	A PHASE 1-2 TRIAL OF DIETHYLSTILBESTROL PLUS LOW DOSE WARFARIN IN ADVANCED PROSTATE CARCINOMA. Journal of Urology, 1999, 161, 169-172.	0.4	60
393	"An individual's sexuality reflects the depths of their soul." Nietzsche. Canadian Journal of Urology, 1999, 6, 718.	0.0	0
394	Office based drug trials. Canadian Journal of Urology, 1999, 6, 826.	0.0	0
395	Diet, androgens, oxidative stress and prostate cancer susceptibility. , 1998, 17, 325-330.		88
396	PREDICTORS OF PATHOLOGICAL STAGE BEFORE NEOADJUVANT ANDROGEN WITHDRAWAL THERAPY AND RADICAL PROSTATECTOMY. Journal of Urology, 1998, 159, 925-928.	0.4	14

#	ARTICLE	IF	CITATIONS
397	Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy. Urology, 1998, 52, 537-542.	1.0	74
398	Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 1998, 338, 1265-1271.	27.0	289
399	"I never go to bed with a girl on the first date, but that's more of a guideline than a rule". Canadian Journal of Urology, 1998, 5, 460.	0.0	0
400	Bacille Calmette-Guerin (BCG) associated epididymitis: a case report and review. Canadian Journal of Urology, 1998, 5, 477-481.	0.0	0
401	Post transurethral resection of prostate incontinence in previously radiated prostate cancer patients. Canadian Journal of Urology, 1998, 5, 560-563.	0.0	8
402	The future of urologic research in Canada:. Canadian Journal of Urology, 1998, 5, 576.	0.0	0
403	PSAdynia and other PSA-related syndromes: A new epidemic? A case history and taxonomy. Urology, 1997, 50, 831-832.	1.0	43
404	EDITORIAL. Canadian Journal of Urology, 1997, 4, 431.	0.0	0
405	EDITORIAL. Canadian Journal of Urology, 1997, 4, 392.	0.0	0
406	Can radiotherapy salvage isolated local recurrence following radical prostatectomy?. Canadian Journal of Urology, 1997, 4, 395-399.	0.0	0
407	EDITORIAL. Canadian Journal of Urology, 1997, 4, 314.	0.0	0
408	Results of a survey of Canadian men with prostate cancer. Canadian Journal of Urology, 1997, 4, 359-365.	0.0	17
409	A multicenter, randomized, double-blind, placebocontrolled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology, 1996, 47, 335-342.	1.0	61
410	Survey of consecutive prostate cancer patients attending the Toronto Sunnybrook Regional Cancer Centre (TSRCC). Canadian Journal of Urology, 1996, 3, 268-276.	0.0	0
411	EDITORIAL. Canadian Journal of Urology, 1996, 3, A7.	0.0	0
412	Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. Canadian Journal of Urology, 1996, 3, 246-250.	0.0	12
413	EDITORIAL. Canadian Journal of Urology, 1996, 3, A9.	0.0	0
414	EDITORIAL. Canadian Journal of Urology, 1996, 3, A7.	0.0	0

#	ARTICLE	IF	CITATIONS
415	EDITORIAL. Canadian Journal of Urology, 1996, 3, A5.	0.0	0
416	Laparoscopic retroperitoneal lymphadenectomy for high-risk stage 1 nonseminomatous germ cell tumor: Report of four cases. Urology, 1994, 43, 752-756.	1.0	26
417	Spontaneous rupture of renal cell carcinoma associated with acute pancreatitis. Urology, 1993, 42, 445-446.	1.0	2
418	Intermittent endocrine therapy for advanced prostate cancer. Cancer, 1986, 58, 2546-2550.	4.1	213